Levacetylmethadolum [Inn-Latin] en es it fr

Levacetylmethadolum [Inn-Latin] Brand names, Levacetylmethadolum [Inn-Latin] Analogs

Levacetylmethadolum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Levacetylmethadolum [Inn-Latin] Chemical_Formula


Levacetylmethadolum [Inn-Latin] RX_link


Levacetylmethadolum [Inn-Latin] fda sheet

Levacetylmethadolum [Inn-Latin] msds (material safety sheet)

Levacetylmethadolum [Inn-Latin] Synthesis Reference

No information avaliable

Levacetylmethadolum [Inn-Latin] Molecular Weight

353.498 g/mol

Levacetylmethadolum [Inn-Latin] Melting Point

No information avaliable

Levacetylmethadolum [Inn-Latin] H2O Solubility

>15 mg/mL

Levacetylmethadolum [Inn-Latin] State


Levacetylmethadolum [Inn-Latin] LogP


Levacetylmethadolum [Inn-Latin] Dosage Forms


Levacetylmethadolum [Inn-Latin] Indication

LAAM is indicated for the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.

Levacetylmethadolum [Inn-Latin] Pharmacology

LAAM is a synthetic synthetic opioid analgesic with multiple actions quantitatively similar to those as morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, LAAM is more active and more toxic than morphine. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The LAAM abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.

Levacetylmethadolum [Inn-Latin] Absorption

LAAM is rapidly absorbed from an oral solution.

Levacetylmethadolum [Inn-Latin] side effects and Toxicity

Signs of overdose include apnea, circulatory collapse, pulmonary edema, cardiac arrest, and death.

Levacetylmethadolum [Inn-Latin] Patient Information

No information avaliable

Levacetylmethadolum [Inn-Latin] Organisms Affected

Humans and other mammals